What is Prodo Laboratories?
Prodo Laboratories, Inc. operates as a specialized service company, providing high-quality human and animal islets essential for advancing diabetes research. The firm collaborates with the Scharp-Lacy Research Institute, offering services that include islet isolations, various assays, and project-based consulting. Their core offerings consist of human islets for research, which are vital for biotechnology and pharmaceutical entities engaged in drug development and the study of insulin-producing cells. Established in 2006, Prodo Labs is committed to enhancing the efficiency of islet isolation techniques and broadening its network of collaborations within the global diabetes research community.
How much funding has Prodo Laboratories raised?
Prodo Laboratories has raised a total of $374K across 2 funding rounds:
Debt
$150K
Debt
$224K
Debt (2020): $150K with participation from PPP
Debt (2021): $224K led by PPP
Key Investors in Prodo Laboratories
PPP
Public-Private Partnership
PPP
Public-Private Partnership
What's next for Prodo Laboratories?
The substantial backing from its recent strategic investment positions Prodo Laboratories for accelerated growth and expanded operational capacity. As a company deeply embedded in the life sciences sector, particularly focusing on diabetes research, this capital infusion is expected to fuel advancements in their service offerings, potentially leading to more efficient islet isolation and greater support for drug discovery initiatives. The company's trajectory suggests a focus on scaling its research support services to meet the growing demands of biotechnology and pharmaceutical partners.
See full Prodo Laboratories company page
